Skip to content

Stefan Borgwardt

Department of Psychiatry and Psychotherapy, University of Lübeck, 23538 Lübeck, Germany.

27 papers in the library · 2,222 citations · publishing 2008-2026

Papers

Lysergic acid diethylamide: In search of the wonder drug

Psychedelics as Psychiatric Medications March 1, 2023 Mihai Avram, Felix Müller, Stefan Borgwardt 1 citation

Lysergic acid diethylamide (LSD) is a potent perception-altering chemical that has been both revered and demonized since its discovery. Before its ban in the late 1960s, it was used to model aspects of psychosis and treat alcohol addiction and anxiety. Recent clinical trials show LSD can be administered safely in clinical settings to healthy volunteers and clinical groups. Small studies suggest potential therapeutic uses for anxiety. LSD's perception-altering effects involve agonism at the 5-HT2A receptor. Neuroimaging reveals LSD enhances signal diversity and complexity, decreases resting-state connectivity within intrinsic brain networks, and increases between-network connectivity, including thalamocortical connectivity.

Für ein besseres Verständnis anhaltender Wahrnehmungsstörungen nach der Einnahme klassischer Psychedelika

Fortschritte der Neurologie · Psychiatrie April 1, 2024 Stefan Borgwardt, Tomislav Majić, Mihai Avram et al.

Classic psychedelics such as psilocybin, LSD, ayahuasca, and 5-MeO-DMT are attracting renewed psychiatric, psychotherapeutic, and neuroscientific interest, driven by recent clinical trials suggesting therapeutic benefits for treatment-resistant depression, substance use disorders, anxiety disorders, and existential distress in life-threatening physical illness. Despite these promising effects, the substances carry unique risks due to the phenomenology of their central nervous system effects, the temporal dynamics of their psychological impacts, and their biological action profile, distinguishing them from many other psychoactive drugs.